Clinically, tumor biopsies from triple negative breast cancer patients treated with neoadjuvant chemotherapy displayed a substantial increase in the frequency of ICOSL+ B cells in comparison to their biopsies before the treatment. The gene discussed is ICOSLG; the disease is triple-negative breast carcinoma.